NVO : Analysis & Opinions

  1. Is This Diabetes Stock a Better Bet Than MannKind?

    May 27, 2015
    MannKind's (NASDAQ: MNKD) inhaled insulin, Afrezza, is incredibly intriguing, but Novo Nordisk's (NYSE: NVO) long-standing ...
  2. Four Key Pharmaceuticals ETFs To Consider

    March 25, 2015
    ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...
  3. Time To Consider Investing In Scandinavia (EWD, EFNL, NORW, EDEN, ...

    October 25, 2013
    The woes in Western Europe were greatly documented during the financial crisis a few years ago. The PIIGS were the countries ...
  4. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  5. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  6. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  7. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  8. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  9. Novo Nordisk A/S and More Big Movers in Healthcare on November ...

    November 6, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has climbed 0.4% and the Dow is trading up 0.6% so far today. The ...
  10. Novo Nordisk A/S (ADR) and Other Big Movers In Healthcare

    August 14, 2012
    The Nasdaq has climbed 0.6%, the S&P 500 is up 0.3% and the Dow has risen 0.3%, marking a bad morning for the market. ...
  11. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  12. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  13. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  14. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  15. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  16. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  17. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  18. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
  19. Investing For The Diabetes Epidemic

    July 30, 2010
    Sadly, diabetes is quickly becoming a global epidemic. Nearly 300 million people suffer from the disease worldwide.
  20. Investing In Scandinavia

    April 29, 2010
    The Scandinavian region is often overlooked from an investment perspective, but it shouldn't be.
  21. Profit Locally, Invest Globally

    June 30, 2008
    As the U.S. equity market drops, overseas stocks appear more and more attractive. We examine a trio of ADRs ready to grow.
Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!